-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $64

Benzinga·09/18/2026 12:24:24
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $69 to $64.